Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

5.2%

11 terminated/withdrawn out of 211 trials

Success Rate

89.3%

+2.8% vs industry average

Late-Stage Pipeline

7%

14 trials in Phase 3/4

Results Transparency

3%

3 of 92 completed trials have results

Key Signals

32 recruiting3 with results10 terminated

Enrollment Performance

Analytics

N/A
63(45.0%)
Phase 2
41(29.3%)
Phase 1
22(15.7%)
Phase 3
9(6.4%)
Phase 4
5(3.6%)
140Total
N/A(63)
Phase 2(41)
Phase 1(22)
Phase 3(9)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (211)

Showing 20 of 211 trials
NCT07540117Not ApplicableRecruiting

Social Prescribing Intervention for Health Promotion in Community-Dwelling Older Adults

Role: lead

NCT07541547Recruiting

Adult Disease Risk Prediction Using Wearables, Hearing, and Health Data

Role: lead

NCT05048901Phase 1Recruiting

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Role: lead

NCT06127446Recruiting

The Registry of Genetic Alterations of Taiwan Ovarian Cancer

Role: lead

NCT05927857Phase 1Recruiting

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

Role: lead

NCT04180072Not ApplicableActive Not Recruiting

Atezolizumab Plus Bevacizumab With HCC and HBV Infection

Role: lead

NCT03406299Phase 2Completed

Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer

Role: lead

NCT07151365Recruiting

Plant-based Diets and Healthy Aging

Role: lead

NCT06271200Not ApplicableRecruiting

Strategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET)

Role: lead

NCT04849481Recruiting

The Research Plan of Taiwan Precision Medicine

Role: lead

NCT05240976Phase 2Recruiting

Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia

Role: collaborator

NCT04745143Phase 2Recruiting

Monotherapy of an NMDA Enhancer for Schizophrenia

Role: collaborator

NCT04446273Not ApplicableRecruiting

Proximal Priority Versus Distal Priority Robotic Priming Effects in Patients With Chronic Stroke

Role: collaborator

NCT07431710Recruiting

The AIR-CPR Study: AI-Guided Chest Compressions

Role: collaborator

NCT07419789Not ApplicableNot Yet Recruiting

Precision Care for Older Persons

Role: collaborator

NCT06756113Not ApplicableCompleted

Digital Dyadic Empowerment Program on Lifestyle Modification for Chronic Kidney Disease Management

Role: collaborator

NCT07369791Phase 2Not Yet Recruiting

Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.

Role: lead

NCT04821895Active Not Recruiting

Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients

Role: lead

NCT05026905Phase 2Active Not Recruiting

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

Role: lead

NCT05522881Recruiting

The Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan

Role: lead